A mutation in the activation loop of the FGFR3 kinase domain (Lysine to Glutamic acid change), leading to constitutive activation of FGFR3, has been identified in patients with multiple myeloma, bladder and cervical carcinomas (Hart et al, 2000). This evidence concerns the gene FGFR3 and AL amyloidosis.